ClinicalTrials.gg
CompletedNCT01776424COMPASSUpdated Nov 28, 2022Results posted

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

A Phase 3 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Rivaroxaban (Xarelto, BAY59-7939) in Prevention & Control, sponsored by Bayer. Completed at 565 sites in 33 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-28.

Sponsored by Bayer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
27,395
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing rivaroxaban in Coronary Artery Disease — 3 open to participants now, 3 under way, none of them phase 3. Rivaroxaban · Coronary Artery Disease.

Enrollment
Largest of 14
27,395 · median 104
Started
2013
with 1 other
Phase 3
3 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
2 of 14
Bayer

Among the 14 studies testing rivaroxaban in Coronary Artery Disease, this one has the largest enrollment, is one of 2 that started in 2013, is one of 3 in phase 3, and was the 2nd registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

3 of the 14 studies testing rivaroxaban in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing rivaroxaban in Coronary Artery Disease, or all of them as a file.
02

Study summary

The primary objectives of this study are:

  • To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with coronary artery disease (CAD) or peripheral artery disease (PAD);
  • To determine whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects with CAD or PAD.
03

Conditions studied

  • Prevention & Control

Keywords

  • Cardiovascular events
  • Rivaroxaban
  • Xarelto
  • Anticoagulant
  • Blood thinner
  • Aspirin
  • ASA
  • Coronary artery disease
  • CAD
  • Peripheral artery disease
  • PAD
  • Artery disease
  • Coronary artery bypass graft
  • Stroke
  • Heart attack
  • Angina
  • Arterial vascular disease
  • Myocardial infarction
  • MI
  • Cardiovascular Death
  • CV Death
  • Heart disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet criteria for CAD and/or PAD

Subjects with CAD must also meet at least one of the following criteria:

  • Age ≥65, or
  • Age \<65 and documented atherosclerosis or revascularization involving at least 2 vascular beds, or at least 2 additional risk factors

Exclusion criteria

Exclusion Criteria:

  • Stroke within 1 month or any history of hemorrhagic or lacunar stroke
  • Severe heart failure with known \<30% or (NYHA) class III or IV symptoms
  • Estimated (eGFR)\<15 mL/min
  • Need for dual antiplatelet therapy, other non-aspirin antiplatelet therapy, or oral anticoagulant therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27,395 participants (actual)

Study arms

  • Experimental
    Rivaroxaban 2.5mg + Aspirin 100mg

    Participants received rivaroxaban 2.5 mg twice daily (bid) and aspirin 100 mg once daily (od). All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a proton pump inhibitor (PPI), were additionally randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.

    Drug: Rivaroxaban (Xarelto, BAY59-7939) · Drug: Aspirin · Drug: Pantoprazole · Drug: Pantoprazole placebo

  • Experimental
    Rivaroxaban 5mg + Aspirin Placebo

    Participants received rivaroxaban 5 mg bid and aspirin placebo od. All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a PPI, were additionally randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.

    Drug: Rivaroxaban (Xarelto, BAY59-7939) · Drug: Aspirin placebo · Drug: Pantoprazole · Drug: Pantoprazole placebo

  • Active comparator
    Rivaroxaban Placebo + Aspirin 100mg

    Participants received rivaroxaban placebo bid and aspirin 100 mg od. All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a PPI, were randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.

    Drug: Aspirin · Drug: Rivaroxaban placebo · Drug: Pantoprazole · Drug: Pantoprazole placebo

Interventions

  • Tablet, 2.5 mg, twice daily, oral

  • Tablet, 5 mg, twice daily, oral

  • Tablet, 100 mg, once daily, oral

  • DrugAspirin placebo

    Aspirin matching placebo, once daily, oral

  • DrugRivaroxaban placebo

    Rivaroxaban matching placebo, twice daily, oral

  • Tablet, 40 mg, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole

  • DrugPantoprazole placebo

    Pantoprazole matching placebo, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole placebo

06

What researchers measure

Primary outcomes

  1. The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

    Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis.

    Time frame: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

  2. The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

    Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day). Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis.

    Time frame: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

Secondary outcomes

  1. The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

    Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis.

    Time frame: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

  2. The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

    Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis.

    Time frame: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

  3. All-cause Mortality

    Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis.

    Time frame: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

Other outcomes

  1. The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

    Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension

    Time frame: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.

  2. The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

    Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day). Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension

    Time frame: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.

  3. All-cause Mortality in LTOLE Part

    Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension

    Time frame: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.

07

Results

Posted Oct 5, 2018
Limitations and caveats
One participant that was included in the Safety Analysis Set in the disclosure after primary completion never took any study drug therefore was corrected in the later analysis.

Participant flow

Study was conducted at 608 centers with randomized participants in 33 countries between 28 Feb 2013 (first patient first visit) and 15 Jun 2021 (last patient last visit of long-term open-label extension part).

Antithrombotic Part (Double Blind)
Participant flow — Antithrombotic Part (Double Blind)
MilestoneRivaroxaban 2.5mg + Aspirin 100mgRivaroxaban 5mg + Aspirin PlaceboRivaroxaban Placebo + Aspirin 100mg
Started915291179126
Treated with antithrombotic treatment913491099107
Randomized to study pantoprazole/placebo587858595861
Completed913290989102
Not completed201924
Withdrew: Lost to follow-up1089
Withdrew: Withdrawal by subject101115
LTOLE Part (Open Label)
Participant flow — LTOLE Part (Open Label)
MilestoneRivaroxaban 2.5mg + Aspirin 100mgRivaroxaban 5mg + Aspirin PlaceboRivaroxaban Placebo + Aspirin 100mg
Started439942924273
Treated in ltole part437942744250
Completed432042304195
Not completed796278
Withdrew: Lost to follow-up625
Withdrew: Refused5211
Withdrew: Missing final visit685862

Outcome measures

PrimaryThe First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis.

Time frame:
For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
Reported as:
Count of participants · Participants
The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death
ParticipantsRivaroxaban 2.5mg + Aspirin 100mgRivaroxaban 5mg + Aspirin PlaceboRivaroxaban Placebo + Aspirin 100mg
The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death379448496
Statistical analysis
  • Rivaroxaban 2.5mg + Aspirin 100mg vs Rivaroxaban Placebo + Aspirin 100mg · Log Rank · p = 0.00004 (Independent DSMB recommended to stop rivaroxaban/aspirin arms on 06FEB2017. At first interim analysis(\~50% events) the log-rank test statistic for one primary comparison had crossed the modified Haybittle-Peto boundary(z=4) consistently over 3 months) · Hazard ratio (hr): 0.76 · 95% CI 0.66 to 0.86Stratified Cox proportional hazards model
  • Rivaroxaban 5mg + Aspirin Placebo vs Rivaroxaban Placebo + Aspirin 100mg · Log Rank · p = 0.11490 · Hazard ratio (hr): 0.90 · 95% CI 0.79 to 1.03Stratified Cox proportional hazards model
PrimaryThe First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day). Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis.

Time frame:
For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
Reported as:
Count of participants · Participants
The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria
ParticipantsRivaroxaban 2.5mg + Aspirin 100mgRivaroxaban 5mg + Aspirin PlaceboRivaroxaban Placebo + Aspirin 100mg
The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria288255170
Statistical analysis
  • Rivaroxaban 2.5mg + Aspirin 100mg vs Rivaroxaban Placebo + Aspirin 100mg · Log Rank · p = <0.00001 · Hazard ratio (hr): 1.70 · 95% CI 1.40 to 2.05Stratified Cox proportional hazards model
  • Rivaroxaban 5mg + Aspirin Placebo vs Rivaroxaban Placebo + Aspirin 100mg · Log Rank · p = 0.00003 · Hazard ratio (hr): 1.51 · 95% CI 1.25 to 1.84Stratified Cox proportional hazards model
SecondaryThe First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis.

Time frame:
For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
Reported as:
Count of participants · Participants
The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death
ParticipantsRivaroxaban 2.5mg + Aspirin 100mgRivaroxaban 5mg + Aspirin PlaceboRivaroxaban Placebo + Aspirin 100mg
The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death329397450
Statistical analysis
  • Rivaroxaban 2.5mg + Aspirin 100mg vs Rivaroxaban Placebo + Aspirin 100mg · Log Rank · p = 0.00001 (Nominal p-value) · Hazard ratio (hr): 0.72 · 95% CI 0.63 to 0.83Stratified Cox proportional hazards model
  • Rivaroxaban 5mg + Aspirin Placebo vs Rivaroxaban Placebo + Aspirin 100mg · Log Rank · p = 0.06437 (Nominal p-value) · Hazard ratio (hr): 0.88 · 95% CI 0.77 to 1.01Stratified Cox proportional hazards model
SecondaryThe First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis.

Time frame:
For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
Reported as:
Count of participants · Participants
The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death
ParticipantsRivaroxaban 2.5mg + Aspirin 100mgRivaroxaban 5mg + Aspirin PlaceboRivaroxaban Placebo + Aspirin 100mg
The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death389453516
Statistical analysis
  • Rivaroxaban 2.5mg + Aspirin 100mg vs Rivaroxaban Placebo + Aspirin 100mg · Log Rank · p = 0.00001 (Nominal p-value) · Hazard ratio (hr): 0.74 · 95% CI 0.65 to 0.85Stratified Cox proportional hazards model
  • Rivaroxaban 5mg + Aspirin Placebo vs Rivaroxaban Placebo + Aspirin 100mg · Log Rank · p = 0.03995 (Nominal p-value) · Hazard ratio (hr): 0.88 · 95% CI 0.77 to 0.99Stratified Cox proportional hazards model
SecondaryAll-cause Mortality

Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis.

Time frame:
For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
Reported as:
Count of participants · Participants
All-cause Mortality
ParticipantsRivaroxaban 2.5mg + Aspirin 100mgRivaroxaban 5mg + Aspirin PlaceboRivaroxaban Placebo + Aspirin 100mg
All-cause Mortality313366378
Statistical analysis
  • Rivaroxaban 2.5mg + Aspirin 100mg vs Rivaroxaban Placebo + Aspirin 100mg · Log Rank · p = 0.01062 (Nominal p-value) · Hazard ratio (hr): 0.82 · 95% CI 0.71 to 0.96Stratified Cox proportional hazards model
  • Rivaroxaban 5mg + Aspirin Placebo vs Rivaroxaban Placebo + Aspirin 100mg · Log Rank · p = 0.66418 (Nominal p-value) · Hazard ratio (hr): 0.97 · 95% CI 0.84 to 1.12Stratified Cox proportional hazards model
Other pre-specifiedThe First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension

Time frame:
For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
Reported as:
Count of participants · Participants
The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part
ParticipantsLTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg
The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part353
Other pre-specifiedThe First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day). Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension

Time frame:
For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
Reported as:
Count of participants · Participants
The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part
ParticipantsLTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg
The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part138
Other pre-specifiedAll-cause Mortality in LTOLE Part

Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension

Time frame:
For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
Reported as:
Count of participants · Participants
All-cause Mortality in LTOLE Part
ParticipantsLTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg
All-cause Mortality in LTOLE Part282

Adverse events

Collected over Adverse events (AEs) are reported: from randomization until 2 days after the last antithrombotic study treatment or until LTOLE part initiation visit (including a mean of 478 days in between) for randomized groups (2 years on average); OR from LTOLE initiation visit up until 2 days after the last treatment for LTOLE group (421 days on average). All-Cause Mortality encompasses all death cases until the last contact (2 years on average for randomized groups; 428 days on average for LTOLE group).. Non-serious events are listed at a 0.1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban 2.5mg + Aspirin 100mg529/9,152 (5.8%)692/9,134 (7.6%)557/9,134 (6.1%)
Rivaroxaban 5mg + Aspirin Placebo566/9,117 (6.2%)664/9,109 (7.3%)529/9,109 (5.8%)
Rivaroxaban Placebo + Aspirin 100mg566/9,126 (6.2%)630/9,107 (6.9%)501/9,107 (5.5%)
LTOLE Rivaroxaban Rivaroxaban 2.5mg + Aspirin 100mg283/12,964 (2.2%)292/12,903 (2.3%)49/12,903 (0.4%)
Most frequent serious events
Showing 10 of 846
Most frequent serious events
EventRivaroxaban 2.5mg + Aspirin 100mgRivaroxaban 5mg + Aspirin PlaceboRivaroxaban Placebo + Aspirin 100mgLTOLE Rivaroxaban Rivaroxaban 2.5mg + Aspirin 100mg
Acute kidney injuryRenal and urinary disorders29/913422/910920/91078/12903
PneumoniaInfections and infestations15/913421/910922/910717/12903
SepsisInfections and infestations18/913418/910917/91076/12903
CataractEye disorders17/913411/91097/91070/12903
Urinary tract infectionInfections and infestations17/913414/91099/91077/12903
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)17/913414/910911/91078/12903
Large intestine polypGastrointestinal disorders8/913414/91099/91071/12903
Chest painGeneral disorders9/913414/91095/91072/12903
AnaemiaBlood and lymphatic system disorders13/913410/91092/91075/12903
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)13/913410/91094/91074/12903
Most frequent other events
Showing 10 of 58
Most frequent other events
EventRivaroxaban 2.5mg + Aspirin 100mgRivaroxaban 5mg + Aspirin PlaceboRivaroxaban Placebo + Aspirin 100mgLTOLE Rivaroxaban Rivaroxaban 2.5mg + Aspirin 100mg
NasopharyngitisInfections and infestations188/9134181/9109195/91070/12903
DiarrhoeaGastrointestinal disorders48/913458/910926/91075/12903
Haemorrhage subcutaneousSkin and subcutaneous tissue disorders49/913418/910917/91070/12903
EpistaxisRespiratory, thoracic and mediastinal disorders38/913429/910924/91071/12903
Back painMusculoskeletal and connective tissue disorders25/913437/910925/91070/12903
ContusionInjury, poisoning and procedural complications37/913422/910927/91072/12903
DizzinessNervous system disorders25/913425/910935/91072/12903
ArthralgiaMusculoskeletal and connective tissue disorders28/913426/910930/91070/12903
Diabetes mellitusMetabolism and nutrition disorders26/913416/910928/91070/12903
Abdominal pain upperGastrointestinal disorders28/913418/910921/91075/12903

Baseline characteristics

Intent-to-treat analysis set (ITT): included all participants randomized to antithrombotic treatment for the initial study part. The ITT set comprised both participants randomized to pantoprazole/placebo and participants not randomized to pantoprazole/placebo.

Age, Continuous
Age, Continuous(Years)Rivaroxaban 2.5mg + Aspirin 100mgRivaroxaban 5mg + Aspirin PlaceboRivaroxaban Placebo + Aspirin 100mgTotal
Mean68.3 ± 7.968.2 ± 7.968.2 ± 8.068.2 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban 2.5mg + Aspirin 100mgRivaroxaban 5mg + Aspirin PlaceboRivaroxaban Placebo + Aspirin 100mgTotal
Female2059197219896020
Male70937145713721375
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rivaroxaban 2.5mg + Aspirin 100mgRivaroxaban 5mg + Aspirin PlaceboRivaroxaban Placebo + Aspirin 100mgTotal
Chinese3883813761145
Hispanic1769175117585278
White/Caucasian56735672568217027
South Asian107102106315
Other Asian9569389152809
Black/African American769492262
Other183179197559
08

Study locations

565 sites
  • Birmingham, Alabama 35294, United States
  • Mobile, Alabama 36608, United States
  • Anaheim, California 92801, United States
  • Laguna Hills, California 92653, United States
  • Northridge, California 91324, United States
  • Palo Alto, California 94304-1207, United States
  • Santa Rosa, California 95494, United States
  • Sylmar, California 91342, United States
  • Torrance, California 90502-2004, United States
  • Norwalk, Connecticut 06851, United States
  • Stamford, Connecticut 06905, United States
  • Trumbull, Connecticut 06611, United States
  • Atlantis, Florida 33462, United States
  • Clearwater, Florida 33756, United States
  • Coral Springs, Florida 33065, United States
  • Jacksonville Beach, Florida 32250, United States
  • Largo, Florida 33770, United States
  • New Port Richey, Florida 34653, United States
  • Safety Harbor, Florida 34695, United States
  • Sarasota, Florida 34239, United States
  • Meridian, Idaho 83716, United States
  • Arlington Heights, Illinois 60005, United States
  • Hazel Crest, Illinois 60429, United States
  • Davenport, Iowa 52803, United States
  • West Des Moines, Iowa 50266, United States
  • Crestview Hills, Kentucky 41017-5460, United States
  • Baltimore, Maryland 21215, United States
  • Haverhill, Massachusetts 01830, United States
  • Alpena, Michigan 49707, United States
  • Jackson, Michigan 49201, United States
  • Saint Louis, Missouri 63136, United States
  • Kalispell, Montana 59901, United States
  • New Brunswick, New Jersey 08901, United States
  • Cortlandt Manor, New York 10567, United States
  • Kingston, New York 12401, United States
  • Saratoga Springs, New York 12866, United States
  • Durham, North Carolina 27713, United States
  • Pinehurst, North Carolina 28374, United States
  • Elyria, Ohio 44035, United States
  • Sandusky, Ohio 44870, United States
  • Toledo, Ohio 43606, United States
  • Doylestown, Pennsylvania 18901, United States
  • Langhorne, Pennsylvania 19047, United States
  • Yardley, Pennsylvania 19067, United States
  • Sioux Falls, South Dakota 57108, United States
  • Dallas, Texas 75216-7167, United States
  • Houston, Texas 77030-4298, United States
  • Houston, Texas 77030, United States
  • San Antonio, Texas 78229, United States
  • Bellevue, Washington 98004-4623, United States
  • Puyallup, Washington 98372, United States
  • Seattle, Washington 98195, United States
  • Spokane, Washington 99204, United States
  • Adrogue, Buenos Aires 1846, Argentina
  • Bahía Blanca, Buenos Aires 8000, Argentina
  • Coronel Suarez, Buenos Aires B7540GHD, Argentina
  • Junín, Buenos Aires B6000BHA, Argentina
  • La Plata, Buenos Aires 1900, Argentina
  • La Plata, Buenos Aires B1902AGY, Argentina
  • La Plata, Buenos Aires B1902CNF, Argentina
  • La Plata, Buenos Aires B1902COS, Argentina
  • Mar del Plata, Buenos Aires B7600FZN, Argentina
  • Merlo, Buenos Aires B1722COV, Argentina
  • Munro, Buenos Aires B1605DSX, Argentina
  • Quilmes, Buenos Aires 1878, Argentina
  • Ramos Mejía, Buenos Aires B1740ETD, Argentina
  • San Martín, Buenos Aires 1650, Argentina
  • San Nicolás, Buenos Aires B2900DMH, Argentina
  • Vicente López, Buenos Aires B1602ABQ, Argentina
  • Zárate, Buenos Aires B2800DGH, Argentina
  • Buenos Aires, Ciudad Auton. De Buenos Aires C1119ACN, Argentina
  • Buenos Aires, Ciudad Auton. De Buenos Aires C1428ART, Argentina
  • Buenos Aires, Ciudad Auton. De Buenos Aires C1440AAD, Argentina
  • Ciudad Autón. de Buenos Aires, Ciudad Auton. De Buenos Aires C1425AGC, Argentina
  • Villa Allende, Córdoba, Argentina
  • Villa María, Córdoba X5900JKA, Argentina
  • Santa Rosa, La Pampa 6300, Argentina
  • Rafaela, Santa Fe S2300MMA, Argentina
  • Rosario, Santa Fe 2000, Argentina
  • Rosario, Santa Fe S2005PAF, Argentina
  • Rosario, Santa Fe, Argentina
  • Venado Tuerto, Santa Fe S2600KUE, Argentina
  • San Miguel de Tucumán, Tucuman 4000, Argentina
  • San Miguel de Tucumán, Tucuman T4000IFL, Argentina
  • Ciudad Auton. de Buenos Aires, C1023AAB, Argentina
  • Ciudad Auton. de Buenos Aires, C1181ACL, Argentina
  • Ciudad Auton. de Buenos Aires, C1405BUB, Argentina
  • Corrientes, 3400, Argentina
  • Córdoba, X5000AAW Córdoba, Argentina
  • Córdoba, X5000AAX, Argentina
  • Córdoba, X5003DCE, Argentina
  • Córdoba, X5003DCP, Argentina
  • Córdoba, X5004CDT, Argentina
  • Córdoba, X5006IKK, Argentina
  • Salta, A4406CLA, Argentina
  • San Juan, 5400, Argentina
  • San luis, 5700, Argentina
  • Santa Fe, S3000FWO, Argentina
  • Bruce, Australian Capital Territory 2617, Australia
  • Gosford, New South Wales 2250, Australia

Showing the first 100 of 565 sites across 33 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Eikelboom JW, Bosch J, Connolly SJ, Tyrwitt J, Fox KAA, Muehlhofer E, Neumann C, Tasto C, Bangdiwala SI, Diaz R, Alings M, Dagenais GR, Leong DP, Lonn EM, Avezum A, Piegas LS, Widimsky P, Parkhomenko AN, Bhatt DL, Branch KRH, Probstfield JL, Lopez-Jaramillo P, Ryden L, Pogosova N, Keltai K, Keltai M, Ertl G, Stoerk S, Dans AL, Lanas F, Liang Y, Zhu J, Torp-Pedersen C, Maggioni AP, Commerford PJ, Guzik TJ, Vanassche T, Verhamme P, O'Donnell M, Tonkin AM, Varigos JD, Vinereanu D, Felix C, Kim JH, Ibrahim KS, Lewis BS, Metsarinne KP, Aboyans V, Steg PG, Hori M, Kakkar A, Anand SS, Lamy A, Sharma M, Yusuf S. Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 2;8(8):786-795. doi: 10.1093/ehjcvp/pvac023. PubMed 35383832 ↗
  • Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V, Abola MT, Branch KRH, Keltai K, Bhatt DL, Verhamme P, Fox KAA, Cook-Bruns N, Lanius V, Connolly SJ, Yusuf S. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. J Am Coll Cardiol. 2018 May 22;71(20):2306-2315. doi: 10.1016/j.jacc.2018.03.008. Epub 2018 Mar 11. PubMed 29540326 ↗
  • Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 Nov 10. pii: S0140-6736(17)32409-1. doi: 10.1016/S0140-6736(17)32409-1. PMID:29132880
  • Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, Metsarinne K, O'Donnell M, Dans AL, Ha JW, Parkhomenko AN, Avezum AA, Lonn E, Lisheng L, Torp-Pedersen C, Widimsky P, Maggioni AP, Felix C, Keltai K, Hori M, Yusoff K, Guzik TJ, Bhatt DL, Branch KRH, Cook Bruns N, Berkowitz SD, Anand SS, Varigos JD, Fox KAA, Yusuf S. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 Nov 10. pii: S0140-6736(17)32458-3. doi: 10.1016/S0140-6736(17)32458-3. PMID:29132879
  • Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Stork S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27. PubMed 28844192 ↗
  • Bosch J, Eikelboom JW, Connolly SJ, Bruns NC, Lanius V, Yuan F, Misselwitz F, Chen E, Diaz R, Alings M, Lonn EM, Widimsky P, Hori M, Avezum A, Piegas LS, Bhatt DL, Branch KRH, Probstfield JL, Liang Y, Liu L, Zhu J, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Fox KAA, Kakkar A, Parkhomenko AN, Ertl G, Stork S, Keltai K, Keltai M, Ryden L, Dagenais GR, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Ha JW, Tonkin AM, Varigos JD, Lewis BS, Felix C, Yusoff K, Steg PG, Aboyans V, Metsarinne KP, Anand SS, Hart RG, Lamy A, Moayyedi P, Leong DP, Sharma M, Yusuf S. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017 Aug;33(8):1027-1035. doi: 10.1016/j.cjca.2017.06.001. Epub 2017 Jun 8. PubMed 28754388 ↗
  • Braunwald E. An Important Step for Thrombocardiology. N Engl J Med. 2017 Oct 5;377(14):1387-1388. doi: 10.1056/NEJMe1710241. Epub 2017 Aug 27. No abstract available. PubMed 28844176 ↗
  • Fauchier L, Bisson A, Angoulvant D. Rivaroxaban in Stable Cardiovascular Disease. N Engl J Med. 2018 Jan 26;378(4):395. doi: 10.1056/NEJMc1714934. No abstract available. PubMed 29372976 ↗
  • Berger JS. Antithrombotic therapy in peripheral artery disease. Lancet. 2018 Jan 20;391(10117):183-184. doi: 10.1016/S0140-6736(17)32847-7. Epub 2017 Nov 10. No abstract available. PubMed 29132877 ↗
  • Darmon A, Bhatt DL, Elbez Y, Aboyans V, Anand S, Bosch J, Branch KR, Connolly SJ, Dyal L, Eikelboom JW, Fox KAA, Keltai K, Probstfield J, Yusuf S, Abtan J, Sorbets E, Eagle KA, Ducrocq G, Steg PG. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur Heart J. 2018 Mar 1;39(9):750-757a. doi: 10.1093/eurheartj/ehx658. PubMed 29186454 ↗
  • Verheugt FWA. Return of Oral Anticoagulation in Chronic Stable Coronary Disease. Circulation. 2018 Apr 17;137(16):1655-1657. doi: 10.1161/CIRCULATIONAHA.117.032916. No abstract available. PubMed 29661947 ↗
  • Fox KAA, Eikelboom JW, Anand SS, Bhatt DL, Bosch J, Connolly SJ, Harrington RA, Steg PG, Yusuf S. Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? Eur Heart J. 2019 May 7;40(18):1466-1471. doi: 10.1093/eurheartj/ehy347. No abstract available. PubMed 29945212 ↗
  • Sharma M, Hart RG, Smith EE, Bosch J, Yuan F, Casanova A, Eikelboom JW, Connolly SJ, Wong G, Diaz R, Lopez-Jaramillo P, Ertl G, Stork S, Dagenais GR, Lonn EM, Ryden L, Tonkin AM, Varigos JD, Bhatt DL, Branch KR, Probstfield JL, Kim JH, Ha JW, O'Donnell M, Vinereanu D, Fox KA, Liang Y, Liu L, Zhu J, Pogosova N, Maggioni AP, Avezum A, Piegas LS, Keltai K, Keltai M, Cook Bruns N, Berkowitz S, Yusuf S. Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. Int J Stroke. 2019 Apr;14(3):270-281. doi: 10.1177/1747493018784478. Epub 2018 Jul 30. PubMed 30058959 ↗
  • Kruger PC, Eikelboom JW, Yusuf S. Rivaroxaban with or without aspirin for prevention of cardiovascular disease. Coron Artery Dis. 2018 Aug;29(5):361-365. doi: 10.1097/MCA.0000000000000605. No abstract available. PubMed 29346127 ↗
  • Ademi Z, Zomer E, Tonkin A, Liew D. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. Int J Cardiol. 2018 Nov 1;270:54-59. doi: 10.1016/j.ijcard.2018.06.091. Epub 2018 Jun 25. PubMed 30220379 ↗
  • Bhagirath VC, Eikelboom JW, Anand SS. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. Future Cardiol. 2018 Nov;14(6):443-453. doi: 10.2217/fca-2018-0059. Epub 2018 Nov 12. PubMed 30417662 ↗
  • Kruger PC, Anand SS, de Vries TAC, Eikelboom JW. Patients with Peripheral Artery Disease in the COMPASS Trial. Eur J Vasc Endovasc Surg. 2018 Dec;56(6):772-773. doi: 10.1016/j.ejvs.2018.08.010. Epub 2018 Sep 10. No abstract available. PubMed 30213508 ↗
  • Boden WE, Bhatt DL. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease? Circulation. 2018 Aug 28;138(9):858-860. doi: 10.1161/CIRCULATIONAHA.118.035405. No abstract available. PubMed 30354448 ↗
  • Lamy A, Eikelboom J, Sheth T, Connolly S, Bosch J, Fox KAA, Zhu J, Lonn E, Dagenais G, Widimsky P, Branch KRH, Bhatt DL, Zheng Z, Straka Z, Dagenais F, Kong Y, Marsden T, Lee SF, Copland I, Yusuf S. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. J Am Coll Cardiol. 2019 Jan 22;73(2):121-130. doi: 10.1016/j.jacc.2018.10.048. PubMed 30654882 ↗
  • Sharma M, Hart RG, Connolly SJ, Bosch J, Shestakovska O, Ng KKH, Catanese L, Keltai K, Aboyans V, Alings M, Ha JW, Varigos J, Tonkin A, O'Donnell M, Bhatt DL, Fox K, Maggioni A, Berkowitz SD, Bruns NC, Yusuf S, Eikelboom JW. Stroke Outcomes in the COMPASS Trial. Circulation. 2019 Feb 26;139(9):1134-1145. doi: 10.1161/CIRCULATIONAHA.118.035864. PubMed 30667279 ↗
  • Coppens M, Weitz JI, Eikelboom JWA. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. Circ Res. 2019 Feb;124(3):416-425. doi: 10.1161/CIRCRESAHA.118.313141. PubMed 30702997 ↗
  • Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Stork S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Cook Bruns N, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar A, Parkhomenko AN, Ryden L, Pogosova N, Dans A, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik T, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne K, Fox KAA, Yusuf S; COMPASS Investigators. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology. 2019 Aug;157(2):403-412.e5. doi: 10.1053/j.gastro.2019.04.041. Epub 2019 May 2. PubMed 31054846 ↗
  • Fox KAA, Eikelboom JW, Shestakovska O, Connolly SJ, Metsarinne KP, Yusuf S. Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. J Am Coll Cardiol. 2019 May 14;73(18):2243-2250. doi: 10.1016/j.jacc.2019.02.048. PubMed 31072566 ↗
  • Cairns JA, Eikelboom JW, Shestakovska O, Yusuf S, DeMets D. Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent. J Am Coll Cardiol. 2019 Jun 4;73(21):2769-2772. doi: 10.1016/j.jacc.2019.03.479. No abstract available. PubMed 31146821 ↗
  • Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Stork S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S; COMPASS Investigators. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019 Sep;157(3):682-691.e2. doi: 10.1053/j.gastro.2019.05.056. Epub 2019 May 29. PubMed 31152740 ↗
  • Kruger PC, Guzik TJ, Eikelboom JW. How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland? Kardiol Pol. 2019 Aug 23;77(7-8):661-669. doi: 10.33963/KP.14855. Epub 2019 May 30. PubMed 31144674 ↗
  • Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK, Bhatt DL, Avezum A, Fox KAA, Connolly SJ, Shestakovska O, Yusuf S. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation. 2019 Aug 13;140(7):529-537. doi: 10.1161/CIRCULATIONAHA.119.039609. Epub 2019 Jun 5. PubMed 31163978 ↗
  • Darmon A, Sorbets E, Ducrocq G, Elbez Y, Abtan J, Popovic B, Ohman EM, Rother J, Wilson PF, Montalescot G, Zeymer U, Bhatt DL, Steg PG; REACH Registry Investigators. Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. J Am Coll Cardiol. 2019 Jul 2;73(25):3281-3291. doi: 10.1016/j.jacc.2019.04.046. PubMed 31248549 ↗
  • Anand SS, Eikelboom JW, Dyal L, Bosch J, Neumann C, Widimsky P, Avezum AA, Probstfield J, Cook Bruns N, Fox KAA, Bhatt DL, Connolly SJ, Yusuf S; COMPASS Trial Investigators. Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. J Am Coll Cardiol. 2019 Jul 2;73(25):3271-3280. doi: 10.1016/j.jacc.2019.02.079. PubMed 31248548 ↗
  • Fox KAA, Metra M, Morais J, Atar D. The myth of 'stable' coronary artery disease. Nat Rev Cardiol. 2020 Jan;17(1):9-21. doi: 10.1038/s41569-019-0233-y. Epub 2019 Jul 29. PubMed 31358978 ↗
  • de Vries TI, Eikelboom JW, Bosch J, Westerink J, Dorresteijn JAN, Alings M, Dyal L, Berkowitz SD, van der Graaf Y, Fox KAA, Visseren FLJ. Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. Eur Heart J. 2019 Dec 7;40(46):3771-3778a. doi: 10.1093/eurheartj/ehz404. PubMed 31504399 ↗
  • Eikelboom JW, Connolly SJ, Bosch J, Shestakovska O, Aboyans V, Alings M, Anand SS, Avezum A, Berkowitz SD, Bhatt DL, Cook-Bruns N, Felix C, Fox KAA, Hart RG, Maggioni AP, Moayyedi P, O'Donnell M, Ryden L, Verhamme P, Widimsky P, Zhu J, Yusuf S. Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation. 2019 Oct 29;140(18):1451-1459. doi: 10.1161/CIRCULATIONAHA.119.041949. Epub 2019 Sep 12. PubMed 31510769 ↗
  • Perera KS, Ng KKH, Nayar S, Catanese L, Dyal L, Sharma M, Connolly SJ, Yusuf S, Bosch J, Eikelboom JW, Hart RG. Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. JAMA Neurol. 2020 Jan 1;77(1):43-48. doi: 10.1001/jamaneurol.2019.2984. PubMed 31524941 ↗
  • Eikelboom JW, Bosch JJ, Connolly SJ, Shestakovska O, Dagenais GR, Hart RG, Leong DP, O'Donnell M, Fox KAA, Bhatt DL, Cairns JA, Tasto C, Berkowitz SD, Cook Bruns N, Muehlhofer E, Diaz R, Maggioni AP, Yusuf S. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. J Am Coll Cardiol. 2019 Sep 24;74(12):1519-1528. doi: 10.1016/j.jacc.2019.07.065. PubMed 31537259 ↗
  • Wurtz M, Olesen KKW, Thim T, Kristensen SD, Eikelboom JW, Maeng M. External applicability of the COMPASS trial: the Western Denmark Heart Registry. Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):192-199. doi: 10.1093/ehjcvp/pvz013. PubMed 30916315 ↗
  • Vanassche T, Verhamme P, Anand SS, Shestakovska O, Fox KA, Bhatt DL, Avezum A, Alings M, Aboyans V, Maggioni AP, Widimsky P, Berkowitz SD, Yusuf S, Connolly SJ, Eikelboom JW, Bosch J. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. Eur J Prev Cardiol. 2020 Feb;27(3):296-307. doi: 10.1177/2047487319882154. Epub 2019 Oct 15. PubMed 31615291 ↗
  • Cowie MR, Lamy A, Levy P, Mealing S, Millier A, Mernagh P, Cristeau O, Bowrin K, Briere JB. Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease. Cardiovasc Res. 2020 Sep 1;116(11):1918-1924. doi: 10.1093/cvr/cvz278. PubMed 31807773 ↗
  • Welsh RC, Peterson ED, De Caterina R, Bode C, Gersh B, Eikelboom JW. Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease. Am Heart J. 2019 Dec;218:100-109. doi: 10.1016/j.ahj.2019.09.006. Epub 2019 Oct 23. PubMed 31715433 ↗
  • Schiele F, Puymirat E, Ferrieres J, Simon T, Fox KAA, Eikelboom J, Danchin N; FAST-MI investigators. The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. Int J Cardiol. 2019 Mar 1;278:7-13. doi: 10.1016/j.ijcard.2018.11.138. Epub 2018 Dec 3. PubMed 30538057 ↗
  • Bainey KR, Welsh RC, Connolly SJ, Marsden T, Bosch J, Fox KAA, Steg PG, Vinereanu D, Connolly DL, Berkowitz SD, Foody JM, Probstfield JL, Branch KR, Lewis BS, Diaz R, Muehlhofer E, Widimsky P, Yusuf S, Eikelboom JW, Bhatt DL; COMPASS Investigators. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation. 2020 Apr 7;141(14):1141-1151. doi: 10.1161/CIRCULATIONAHA.119.044598. Epub 2020 Mar 17. Erratum In: Circulation. 2020 Jun 9;141(23):e905. doi: 10.1161/CIR.0000000000000847. PubMed 32178526 ↗
  • Liang Y, Zhu J, Liu L, Anand SS, Connolly SJ, Bosch J, Guzik TJ, O'Donnell M, Dagenais GR, Fox KA, Shestakovska O, Berkowitz SD, Muehlhofer E, Keller L, Yusuf S, Eikelboom JW; COMPASS Investigators. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. Cardiovasc Res. 2021 Feb 22;117(3):942-949. doi: 10.1093/cvr/cvaa100. Erratum In: Cardiovasc Res. 2021 May 25;117(6):1577. doi: 10.1093/cvr/cvaa182. PubMed 32289159 ↗
  • Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, Branch KRH, Probstfield J, Bosch J, Shestakovska O, Szarek M, Maggioni AP, Widimsky P, Avezum A, Diaz R, Lewis BS, Berkowitz SD, Fox KAA, Ryden L, Yusuf S; COMPASS Steering Committee and Investigators. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. Circulation. 2020 Jun 9;141(23):1841-1854. doi: 10.1161/CIRCULATIONAHA.120.046448. Epub 2020 Mar 28. PubMed 32223318 ↗
  • Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA. The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease. Circulation. 2020 Jul 7;142(1):40-48. doi: 10.1161/CIRCULATIONAHA.120.046048. Epub 2020 May 21. Erratum In: Circulation. 2020 Jul 7;142(1):e23. doi: 10.1161/CIR.0000000000000880. PubMed 32436455 ↗
  • Sharma M, Hart RG, Smith EE, Bosch J, Eikelboom JW, Connolly SJ, Dyal L, Reeh KW, Casanova A, Diaz R, Lopez-Jaramillo P, Ertl G, Stork S, Dagenais GR, Lonn EM, Ryden L, Tonkin AM, Varigos JD, Bhatt DL, Branch KRH, Probstfield JL, Kim JH, O'Donnell M, Vinereanu D, A A Fox K, Liang Y, Liu L, Zhu J, Pogosova N, Maggioni AP, Avezum A, Piegas LS, Keltai K, Keltai M, Berkowitz SD, Yusuf S. Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. Stroke. 2020 Oct;51(10):2901-2909. doi: 10.1161/STROKEAHA.120.029762. Epub 2020 Sep 21. Erratum In: Stroke. 2021 Jan;52(2):e90. doi: 10.1161/STR.0000000000000360. PubMed 32951537 ↗
  • Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme P, Avezum A, Fox KAA, Berkowitz SD, Bangdiwala SI, Yusuf S, Anand SS. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. JAMA Cardiol. 2021 Jan 1;6(1):21-29. doi: 10.1001/jamacardio.2020.4390. Erratum In: JAMA Cardiol. 2021 Feb 1;6(2):246. doi: 10.1001/jamacardio.2020.6442. PubMed 32997098 ↗
  • Guzik TJ, Ramasundarahettige C, Pogosova N, Lopez-Jaramillo P, Dyal L, Berkowitz SD, Muehlhofer E, Bhatt DL, Fox KAA, Yusuf S, Eikelboom JW. Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. J Am Coll Cardiol. 2021 Feb 9;77(5):511-525. doi: 10.1016/j.jacc.2020.11.061. PubMed 33538248 ↗
  • Sen J, Tonkin A, Varigos J, Fonguh S, Berkowitz SD, Yusuf S, Verhamme P, Vanassche T, Anand SS, Fox KAA, Eikelboom JW, Amerena J; COMPASS Trial Investigators. Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease. Int J Cardiol. 2021 Aug 15;337:9-15. doi: 10.1016/j.ijcard.2021.04.067. Epub 2021 May 3. PubMed 33957178 ↗
  • Dagenais GR, Dyal L, Bosch JJ, Leong DP, Aboyans V, Berkowitz SD, Bhatt DL, Connolly SJ, Fox KAA, Muehlhofer E, Probstfield JL, Widimsky P, Winkelmann BR, Yusuf S, Eikelboom JW. Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart. 2021 Jul;107(14):1130-1137. doi: 10.1136/heartjnl-2020-318758. Epub 2021 May 21. PubMed 34021038 ↗
  • Lamy A, Browne A, Sheth T, Zheng Z, Dagenais F, Noiseux N, Chen X, Bakaeen FG, Brtko M, Stevens LM, Alboom M, Lee SF, Copland I, Salim Y, Eikelboom J; COMPASS Investigators. Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery: A Post Hoc Analysis From the COMPASS Trial. JAMA Cardiol. 2021 Sep 1;6(9):1042-1049. doi: 10.1001/jamacardio.2021.1686. Erratum In: JAMA Cardiol. 2021 Oct 1;6(10):1223. doi: 10.1001/jamacardio.2021.3351. PubMed 34132753 ↗
  • Vanassche T, Verhamme P, Anand SS, Shestakovska O, Leong DP, Fox KAA, Bhatt DL, Avezum A, Alings M, Aboyans V, Maggioni AP, Widimsky P, Muehlhofer E, Berkowitz SD, Yusuf S, Connolly SJ, Eikelboom JW, Bosch J. Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. Eur Heart J Cardiovasc Pharmacother. 2022 Aug 11;8(5):462-473. doi: 10.1093/ehjcvp/pvab050. PubMed 34191011 ↗
  • Eikelboom JW, Bhatt DL, Fox KAA, Bosch J, Connolly SJ, Anand SS, Avezum A, Berkowitz SD, Branch KRH, Dagenais GR, Felix C, Guzik TJ, Hart RG, Maggioni AP, Muehlhofer E, Sharma M, Shestakovska O, Yusuf S. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. J Am Coll Cardiol. 2021 Jul 6;78(1):14-23. doi: 10.1016/j.jacc.2021.04.083. PubMed 34210409 ↗
  • Anand SS, Hiatt W, Dyal L, Bauersachs R, Berkowitz SD, Branch KRH, Debus S, Fox KAA, Liang Y, Muehlhofer E, Nehler M, Haskell LP, Patel M, Szarek M, Yusuf S, Eikelboom J, Bonaca MP. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. Eur J Prev Cardiol. 2022 May 5;29(5):e181-e189. doi: 10.1093/eurjpc/zwab128. PubMed 34463737 ↗
  • Kaplovitch E, Anand SS. The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era. Cardiovasc Res. 2019 Oct 1;115(12):e121-e124. doi: 10.1093/cvr/cvz170. No abstract available. PubMed 31321405 ↗
  • Lamy A, Eikelboom J, Tong W, Yuan F, Bangdiwala SI, Bosch J, Connolly S, Lonn E, Dagenais GR, Branch KRH, Wang WJ, Bhatt DL, Probstfield J, Ertl G, Stork S, Steg PG, Aboyans V, Durand-Zaleski I, Ryden L, Yusuf S. The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial. Eur Heart J Qual Care Clin Outcomes. 2023 Aug 7;9(5):502-510. doi: 10.1093/ehjqcco/qcac054. PubMed 36001989 ↗
  • Catanese L, Eikelboom JW, Bosch J, Shestakovska O, Ng K, Nayar S, Perera KS, Shoamanesh A, Sharma M, Hart RG. Oral factor Xa inhibitors and risk of subdural hematoma: COMPASS trial results and meta-analysis. Neurology. 2020 Aug 4;95(5):e480-e487. doi: 10.1212/WNL.0000000000009826. Epub 2020 Jul 10. PubMed 32651298 ↗
  • Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Stork S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):219-229. doi: 10.1016/S0140-6736(17)32409-1. Epub 2017 Nov 10. PubMed 29132880 ↗
  • Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, Metsarinne K, O'Donnell M, Dans AL, Ha JW, Parkhomenko AN, Avezum AA, Lonn E, Lisheng L, Torp-Pedersen C, Widimsky P, Maggioni AP, Felix C, Keltai K, Hori M, Yusoff K, Guzik TJ, Bhatt DL, Branch KRH, Cook Bruns N, Berkowitz SD, Anand SS, Varigos JD, Fox KAA, Yusuf S; COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):205-218. doi: 10.1016/S0140-6736(17)32458-3. Epub 2017 Nov 10. Erratum In: Lancet. 2018 Jan 20;391(10117):204. doi: 10.1016/S0140-6736(17)33365-2. PubMed 29132879 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2013 to primary completion in Jul 2017, 52 months.

Results were first posted in Oct 2018, 1 year 2 months after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Coronary Artery Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's 52 months is close to that.

Counting every sponsor, half of 61 studies reached it within 47 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2013
First posted
Jan 28, 2013
StartActual
Feb 28, 2013
Primary completionActual
Jul 21, 2017
CompletionActual
Jun 15, 2021
Results first posted
Oct 5, 2018
Last update
Nov 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01776424
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 28, 2013
Start date
Feb 28, 2013
Primary completion
Jul 21, 2017
Completion
Jun 15, 2021
Results posted
Oct 5, 2018
Last update
Nov 28, 2022

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rivaroxaban · Aspirin

Start the discussion